Nothing Special   »   [go: up one dir, main page]

ATE481645T1 - Biomarker für den frühzeitigen nachweis von ovarialkarzinom - Google Patents

Biomarker für den frühzeitigen nachweis von ovarialkarzinom

Info

Publication number
ATE481645T1
ATE481645T1 AT05771584T AT05771584T ATE481645T1 AT E481645 T1 ATE481645 T1 AT E481645T1 AT 05771584 T AT05771584 T AT 05771584T AT 05771584 T AT05771584 T AT 05771584T AT E481645 T1 ATE481645 T1 AT E481645T1
Authority
AT
Austria
Prior art keywords
stage
patients
ovarian
biomarrkers
early detection
Prior art date
Application number
AT05771584T
Other languages
English (en)
Inventor
Robin Farias-Eisner
Srinivasa Reddy
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE481645T1 publication Critical patent/ATE481645T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05771584T 2004-07-14 2005-07-14 Biomarker für den frühzeitigen nachweis von ovarialkarzinom ATE481645T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58800704P 2004-07-14 2004-07-14
US67448905P 2005-04-25 2005-04-25
PCT/US2005/024985 WO2006019906A1 (en) 2004-07-14 2005-07-14 Biomarker for early detection of ovarian cancer

Publications (1)

Publication Number Publication Date
ATE481645T1 true ATE481645T1 (de) 2010-10-15

Family

ID=35406265

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05771584T ATE481645T1 (de) 2004-07-14 2005-07-14 Biomarker für den frühzeitigen nachweis von ovarialkarzinom

Country Status (6)

Country Link
US (3) US8323915B2 (de)
EP (5) EP3203241A1 (de)
AT (1) ATE481645T1 (de)
DE (1) DE602005023629D1 (de)
DK (1) DK2199801T3 (de)
WO (1) WO2006019906A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9488655B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
US9487575B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
WO2007002264A2 (en) 2005-06-22 2007-01-04 The Johns Hopkins University Biomarker for ovarian cancer: ctap3-related proteins
WO2008123948A1 (en) 2007-03-27 2008-10-16 Vermillion, Inc. Biomarkers for ovarian cancer
KR100997463B1 (ko) * 2007-04-30 2010-11-30 (주)예비티 난소암 진단용 조성물, 그 키트 및 진단 방법
EP2220506B1 (de) * 2007-10-29 2013-10-02 Vermillion, Inc. Biomarker zum nachweis von ovarialkarzinom im frühstadium
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
JP2013541716A (ja) * 2010-10-22 2013-11-14 ヴァーミリオン インコーポレイテッド 卵巣癌の患者における予後予測バイオマーカー
JP6092198B2 (ja) * 2011-06-10 2017-03-08 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 新規カラーコンバーター
CA2846865A1 (en) 2011-08-29 2013-03-07 The Regents Of The University Of California Use of hdl-related molecules to treat and prevent proinflammatory conditions
US9789175B2 (en) * 2013-03-15 2017-10-17 The Trustees Of The University Of Pennsylvania Synthetic immunogens for prophylaxis or treatment of tuberculosis
US20150153348A1 (en) * 2013-12-04 2015-06-04 Vermillion, Inc. BIOMARKERS FOR OVARIAN CANCER: Beta 2 MICROGLOBULIN
RU2576821C2 (ru) * 2014-06-30 2016-03-10 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения Российской Федерации" (ФГБУ "МНИОИ им. П.А. Герцена" Минздрава России) Способ определения эффективности консервативного лечения рака не увеличенных яичников

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DK145385D0 (da) * 1985-03-29 1985-04-01 Novo Industri As Monoklonalt antistof til immunkemisk analyse
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5114863A (en) * 1986-09-30 1992-05-19 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Immunosorbant assay for α-1-antitrypsin, kit employing said assay, monoclonal antibody to α-1-antitrypsin, and hybridoma for producing said monoclonal antibody
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
WO1989006280A1 (en) 1988-01-04 1989-07-13 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
EP1645635A3 (de) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replikationdefiziente Rekombinante Retroviren, die eine palliative Wirkung exprimieren
SE8904007D0 (sv) * 1989-11-28 1989-11-28 Ferring Ab Monoklona antikroppar och diagnostiseringsmetod
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE154698T1 (de) 1990-10-18 1997-07-15 Cellpro Inc Vorrichtung und verfahren zur trennung von partikeln mittels eines biegsamen gefässes
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US20030027216A1 (en) * 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US5955582A (en) * 1997-09-26 1999-09-21 Beckman Coulter, Inc. Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay
GB9805877D0 (en) * 1998-03-20 1998-05-13 Imp Cancer Res Tech Cancer
AU772548B2 (en) * 1998-12-22 2004-04-29 Daiichi Pure Chemicals Co., Ltd. Monoclonal antibody against apolipoprotein A-I
WO2002088750A2 (en) * 2001-05-02 2002-11-07 Oxford Glycosciences (Uk) Ltd Proteins, genes and their use for diagnosis and treatment of breast cancer
US20050214760A1 (en) * 2002-01-07 2005-09-29 Johns Hopkins University Biomarkers for detecting ovarian cancer
US7291461B2 (en) * 2002-06-21 2007-11-06 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mRNA decay
JP2006512895A (ja) * 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
CA2493808A1 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mrna decay
EP1540010B8 (de) * 2002-08-06 2010-07-14 The Johns Hopkins University Verwendung von biomarkern zum nachweis von eierstockkrebs
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
CA2525385A1 (en) * 2003-05-12 2004-11-25 The Children's Hospital Of Philadelphia Grp94-based compositions and methods of use thereof
ATE416384T1 (de) * 2003-08-25 2008-12-15 Marc Ramael Verfahren und kit zum quantitativen und/oder qualitativen nachweis von komponenten in einer probe
US20060147946A1 (en) * 2004-01-27 2006-07-06 Pinchas Akiva Novel calcium channel variants and methods of use thereof
WO2005093413A2 (en) * 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
WO2006071247A2 (en) * 2004-03-30 2006-07-06 California Institute Of Technology Diagnostic assays including multiplexed lateral flow immunoassays with quantum dots
US20060094039A1 (en) * 2004-09-20 2006-05-04 Ron Rosenfeld Diagnosis of fetal aneuploidy
NZ560976A (en) * 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
US7604948B2 (en) * 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
US7575876B2 (en) * 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders

Also Published As

Publication number Publication date
US20160069886A1 (en) 2016-03-10
EP2199801A2 (de) 2010-06-23
DE602005023629D1 (de) 2010-10-28
EP2199801B1 (de) 2013-05-29
US9110083B2 (en) 2015-08-18
EP2199801A3 (de) 2010-08-25
EP2848942B1 (de) 2017-03-08
EP1789805B1 (de) 2010-09-15
WO2006019906A1 (en) 2006-02-23
EP2261672A2 (de) 2010-12-15
EP2261672A3 (de) 2011-10-05
EP1789805A1 (de) 2007-05-30
EP2261672B1 (de) 2014-09-03
DK2199801T3 (da) 2013-08-05
US8323915B2 (en) 2012-12-04
US20100081151A1 (en) 2010-04-01
EP3203241A1 (de) 2017-08-09
EP2848942A1 (de) 2015-03-18
US20130090256A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
ATE481645T1 (de) Biomarker für den frühzeitigen nachweis von ovarialkarzinom
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
DE60214134D1 (de) Modifizierte psma-liganden und deren verwendung
SG165370A1 (en) Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
ATE553382T1 (de) Verwendungen von krebsspezifischen glykanen
DE69938187D1 (de) Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen
DE602006018578D1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
ATE513216T1 (de) Verwendung des proteins satb2 als prognostischer marker für kolorektalkarzinome
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
WO2005034732A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
ATE522620T1 (de) Nachweis von micrometastasierung von melanomen und brustkrebs an in paraffin eingegbetteten, von tumoren abführenden lymphknoten mittels quantitativer multimaker rt-pcr
Bernacki et al. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma
DE60032784D1 (de) Markerproteine für prostatakrebs
MY193895A (en) Combination test for colorectal cancer
Chia et al. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors
WO2003021229A3 (en) Diagnostic and prognostic tests
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
DE602004022632D1 (de) Verwendung von adiponectin zur diagnose von krebs
ATE491727T1 (de) Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
Zhang et al. A new scoring method for personalized prognostic prediction in patients with combined hepatocellular and cholangiocarcinoma after surgery
Kang et al. Prognostic role of neutrophil-to-lymphocyte ratio-based markers during pre-and postadjuvant chemotherapy in patients with advanced urothelial carcinoma of upper urinary tract
Chen et al. Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study
ATE503186T1 (de) Verwendung neuartiger biomarker zum nachweis von hodenkrebs in situ und abgeleiteten krebserkrankungen in menschlichen proben

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties